相关实验视频

Updated: Jul 4, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

卡洛思B衍生物通过ERK/Ras/Raf/MEK通路诱导HEL细胞的亡和细胞循环停止

Bo Wang¹, Ming Wang², Ke Li³

¹State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China; Natural Products Research Center of Guizhou Province, Guiyang 550014, China; College of Basic Medical, Guizhou Medical University, Guizhou 550004, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|January 26, 2024

概括

一种新型化合物H-107,来自Calothrixin B,显示承诺作为一种化学治疗急性红血球白血病 (AEL). 它有效地抑制白血病细胞的增殖,并在临床前模型中促进红色球体分化.

科学领域:

药用化学医学化学
血液学血液学血液学
癌症生物学癌症生物学

背景情况:

急性红血球白血病 (AEL) 是一种急性髓性白血病的亚型,预后不佳,特别是在老年人中.
卡洛思B是一种天然化合物,表现出抗癌性质,作为合成新型治疗剂的头.
迫切需要新的化疗选择来提高AEL患者的生存率.

研究的目的:

合成新型卡洛思B衍生物作为潜在的抗白血病药物.
为了评估这些衍生品对急性红血病细胞系和动物模型的疗效.
为了阐明最强大的衍生品的作用机制.

主要方法:

合成卡洛思B衍生物及其抗繁殖活性的评估.
通过MTT测定,流细胞计和西白斑检测,评估细胞亡,细胞循环停止和线粒体损伤.
在小鼠体内研究,包括脏分析,HE染色和血清生物化学指数检测.

主要成果:

H-107对HEL细胞表现出显著的抗白血病活性 (IC50 = 3.63μM),诱导了细胞亡和G0/G1细胞周期停止.
H-107通过ERK/Ras/Raf/MEK通路起作用,降低像c-Myc这样的关键蛋白质的下调,并激活酶级联.
在体内,H-107促进了红细胞分化,并增强了红细胞白血病小鼠的免疫细胞活性.

结论:

H-107是一种强效的卡洛思B衍生物,具有显著的抗红血球白血病活性.
H-107具有双重的作用机制,抑制增殖和促进分化.
H-107代表了一种有前途的新型化疗候选人,用于治疗急性红血球白血病.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.卡洛特里辛B是一种细胞循环的细胞周期埃尔克·埃尔克是什么意思红血球白血病红血球白血病

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling

Published on: June 25, 2015

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

The Extrinsic Apoptotic Pathway

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...